EMA accepts under Accelerated Assessment of MAA for UM171 Cell Therapy for patients with heme malignancies who lack a readily available suitable donor July 1, 2024
New Efficacy Data For RCC From KEYNOTE-B61 Added To Lenvima® (Lenvatinib) US Label Supporting Keytruda + Lenvima Indication For The 1L Treatment July 1, 2024
Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer based on CAPItello-291 results June 25, 2024
FDA Approves KEYTRUDA® + Carboplatin + Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma June 25, 2024
EU approves FRUZAQLA in Previously Treated Metastatic Colorectal Cancer Based on Results from Ph 3 FRESCO-2 Trial June 25, 2024
FDA grants Accelerated Approval to KRAZATI® (adagrasib) + Cetuximab for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic CRC June 25, 2024
US FDA Approves Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors June 18, 2024
Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer June 18, 2024
FDA approved blinatumomab in the consolidation phase of multiphase chemo for adult & pediatric patients with CD19+ve Ph–neg B-cell precursor ALL June 18, 2024
European Commission approves Alecensa as the adjuvant treatment for people with ALK-positive early-stage lung cancer June 18, 2024
Tagrisso with the addition of chemo recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer June 11, 2024
European Commission Approves Opdivo, Cisplatin and Gemcitabine combo for the 1L Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma June 4, 2024
WITHDRAWN: FDA withdraws accelerated approval to infigratinib for metastatic cholangiocarcinoma May 21, 2024
FDA approves Imdelltra™ (tarlatamab-dlle) for The Treatment Of Extensive-Stage Small Cell Lung Cancer May 21, 2024
Approvals received for BRAFTOVI and MEKTOVI for Expanded Use for Two New Indications in Japan May 21, 2024
FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer May 15, 2024
CARVYKTI (ciltacabtagene autoleucel) Approved by the European Commission for 2L Treatment of Patients with R/R Multiple Myeloma May 1, 2024
Vebreltinib approved in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene May 1, 2024
